Amorphous 3-pyridil-1-hydroxyethyliden-1,1-biphosphonic acid...

Details Amorphous 3-pyridil-1-hydroxyethyliden-1,1-biphosphonic acid... Amorphous 3-pyridil-1-hydroxyethyliden-1,1-biphosphonic acid...

2005-02-28

2010-12-28

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S022000

Reexamination Certificate

active

07858634

ABSTRACT:
A process for the preparation of 3-pyridil-1-hydroxyethyliden-1,1-biphosphonic acid monosodium salt of formulain an amorphous form, preferably lyophilized, and its pharmaceutical compositions are described. Said amorphous form, characterized by stability and simplicity of preparation and formulation, can be obtained by an industrially applicable lyophilization process, which comprises the steps of:a) dissolving or suspending 3-pyridyl-1-hydroxyethyliden-1,1-biphosphonic acid in an aqueous solvent,b) adding one equivalent of a base having sodium as cationc) subjecting the solution to lyophilization.

REFERENCES:
patent: 5368587 (1994-11-01), Lechleiter
patent: 5756737 (1998-05-01), Turchetta et al.
patent: 6583287 (2003-06-01), Rossi et al.
patent: 6897339 (2005-05-01), Turchetta et al.
patent: 7105681 (2006-09-01), Turchetta et al.
patent: 7241805 (2007-07-01), Oberegger et al.
patent: 7332603 (2008-02-01), De Ferra et al.
patent: 7358399 (2008-04-01), Turchetta et al.
patent: 7417149 (2008-08-01), Turchetta et al.
patent: 2005/0142185 (2005-06-01), Beleno et al.
patent: 0186405 (1986-02-01), None
patent: 0186405 (1986-07-01), None
patent: WO-03/033508 (2003-04-01), None
patent: WO-03/086355 (2003-10-01), None
patent: WO-2005/082915 (2005-09-01), None
Howley's “condesed chemical dictionary” p. 68 (1997).
Merck manuel “urollithiasis” (2008) internet print out 5 pages.
Doelker et al. “Crystalline modification . . . ” CA 138:209993 (2002).
Perkins et al. “Esophagial transit . . . ” Int. J. Pharm. 186, p. 169-175 91999).
Lieberman et al. “Pharmaceutical dosage forms” p. 462-465 (1989).
SSCI “screening for amorphous drug . . . ” p. 1-3 (2003).
SSCI “Amorphous solids . . . ” p. 1-3 (2003).
Exhibit I.
Medical Device “Liphilization” (2009) p. 1 from internet.
GEA “test center for lyophilization application support” p. 1-2 from internet (2009).
Ma et al.“Effects of . . . ” Sci. Search AN04464647 Abstract (1995).
Nakamura et al. “Osteroprotegrin . . . ” Sci Search. AN 12263872, abstract (2003).
Osteoporosis Prevention, Diagnosis, and Therapy, American Medical Association, 2001, vol. 285, No. 6, pp. 785-796.
M. Rossini, et al., “Effects of Oral Alendronate in Elderly Patients with Osteoporosis and Mild Primary Hyperparathyroidism,”Journal of Bone and Mineral Research, 2001, Volume, No. 1, pp. 113-119.
S. Boonen, et al., “Age-Related (Type II) Femoral Neck Osteoporosis in Men: Biochemical Evidence for Both Hypovitaminiosis D- and Androgen Deficiency—Induced Bone Resporption,”Journal of Bone and Mineral Research, 1997, vol. 12, No. 12, pp. 2119-2126.
M. Gupta, et al. “Inhibition of calcium oxalate urolithiasis in a rat model of lithogenesis using bisphosphonates,”J Endourol., 1997; 11(1):1-4 (ISSN: 0892-7790).
Gambacorta, A., et al.; “Silica Supported Tetrabutylammonium Fluoride as a Catalyst for the Silylation of Carbonyl and Hydroxy Compounds with Ethyltrimethylsilylacetate”; Synth. Commun.; 1989; pp. 2441-2448.
Gambacorta, A., et al.; “Bicyclo [3.3.1] Nonane Approach to Pinguisane Terpenoids, Total Synthesis of (±) Pinguisone”; Tetrahedron; 1988; vol. 44, No. 15; pp. 4837-4846.
Gambacorta, A., et al.; “Bicyclo [3.3.1] Nonanes as Synthetic Intermediates Synthesis of 1-Hydroxy-Anti-8-Acetylbicyclo [4.2.2] Decane”; Tetrahedron Letters; 1991; vol. 32, No. 46; pp. 6805-6808; 1991.
Gambacorta, A., et al.; “Synthesis of Substituted cis-Bicyclo [3.3.0] Octane-1-Carbonyl Derivatives by Stereospecific Rearrangement of 1-Chloro-9-Hydroxybicyclo [3.3.1] Nonanes”; Tetrahedron; 1991; vol. 47, No. 43; pp. 9097-9102.

Affiliated with

Also associated with

Rating

Amorphous 3-pyridil-1-hydroxyethyliden-1,1-biphosphonic acid... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amorphous 3-pyridil-1-hydroxyethyliden-1,1-biphosphonic acid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amorphous 3-pyridil-1-hydroxyethyliden-1,1-biphosphonic acid... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4184422